According to the study the vaccine candidate is delivered intramuscularly, and enables human cells to produce proteins part of the SARS-CoV-2 receptor-binding domain, against which the immune system is trained to produce antibodies.
Pfizer-BioNTech vaccine candidate induces immune response in early-phase clinical trial: Study
